JAKAVI 5 MG TABS 10'S

About

Jakavi (ruxolitinib) 5 MG is a potent Janus kinase (JAK) inhibitor that specifically targets JAK1 and JAK2, enzymes critical in cell signaling pathways involved in hematopoiesis and immune function. By inhibiting these kinases, ruxolitinib effectively reduces the symptoms and splenomegaly associated with myelofibrosis and polycythemia vera, two chronic myeloproliferative neoplasms characterized by abnormal blood cell production and inflammation. This targeted therapy helps to normalize blood counts, reduce spleen size, and alleviate debilitating constitutional symptoms such as fatigue, night sweats, and pruritus, significantly improving patients' quality of life.

Its mechanism of action directly addresses the underlying pathological drivers of these diseases, offering a crucial treatment option for patients who often have limited therapeutic alternatives. Jakavi represents a significant advancement in the management of these complex hematological disorders.

Uses

• Treatment of intermediate or high-risk myelofibrosis
• Management of polycythemia vera in specific cases
• Treatment of acute and chronic graft-versus-host disease
• Off-label use in certain chronic myeloid leukemia cases

Directions For Use

Take orally twice daily with or without food, as prescribed by your oncologist or hematologist.

Benefits

• Significantly reduces splenomegaly
• Alleviates debilitating constitutional symptoms
• Improves overall quality of life
• Effective in myelofibrosis patients
• Effective in polycythemia vera patients
• Targets specific disease-driving pathways

Side Effects

• Thrombocytopenia (low platelet count)
• Anemia (low red blood cell count)
• Neutropenia (low white blood cell count)
• Bruising or bleeding
• Dizziness
• Headache
• Diarrhea
• Fatigue
• Weight gain
• Increased liver enzymes
• Urinary tract infection
• Herpes zoster reactivation

Safety Measures

• Alcohol - Avoid or limit alcohol consumption due to potential for increased liver toxicity and gastrointestinal irritation.
• Pregnancy - Contraindicated; can cause fetal harm. Women of childbearing potential must use effective contraception during treatment and for at least one month after.
• Breastfeeding - Not recommended; discontinue breastfeeding during treatment with Jakavi due to potential harm to the infant.
• Liver - Use with caution and require dose adjustment in patients with severe liver impairment; monitor liver function closely.
• Kidney - Use with caution and require dose adjustment in patients with severe kidney impairment; monitor kidney function closely.
• Lung - Monitor for non-infectious pneumonitis; use with caution in patients with pre-existing lung conditions or history of lung disease.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.